Penumbra Board Urges Shareholders to Vote FOR Boston Scientific Merger, Warns Abstention Counts as Opposition

**TL;DR** Penumbra's Board of Directors unanimously recommends shareholders approve the proposed merger with Boston Scientific. The board underscored that not casting a vote at the May 6, 2026, special meeting will count as an opposing vote.

**Context** Penumbra shareholders face a crucial decision regarding the company's proposed merger with Boston Scientific Corporation. This transaction represents a significant strategic shift, and its approval hinges on active participation from the investor base. The board's recent communication aims to clarify the importance of each shareholder's vote.

**Key Facts** Penumbra's Board of Directors has issued a unanimous recommendation, urging all stockholders to vote in favor of the merger with Boston Scientific. This collective endorsement signals the board's conviction that the proposed acquisition offers substantial benefits for the company and its investors.

A critical procedural detail for all stockholders is that failing to cast a vote in the special meeting carries the same legal weight as a direct vote against the merger. Shareholders must actively submit their preference for their vote to be counted as intended, whether for or against the proposal.

The special meeting to vote on this pivotal merger is firmly scheduled for May 6, 2026. This date marks the definitive deadline for shareholders to formally register their decision on the acquisition, shaping Penumbra's future trajectory.

**What It Means** This clear directive from Penumbra's board seeks to solidify shareholder support for the merger. The explicit warning about abstention underscores the need for proactive engagement, ensuring that only intentional decisions influence the outcome.

The board's unanimous recommendation positions the proposed merger as the strategic preference for the company's future. This guidance provides a unified front from leadership, urging investors to align with their assessment of the transaction's value. Shareholders now hold the direct power to approve or reject this significant corporate event.

Market observers will closely track Penumbra's shareholder engagement efforts leading up to May 6, 2026. The final vote tally will not only determine the immediate future of Penumbra but also set a precedent for investor participation in major corporate actions.